The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET(sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.
RET TKI: potential role in thyroid cancers / Antonelli, A; Fallahi, P; Ferrari, Silvia Martina; Mancusi, C; Colaci, Michele; Santarpia, L; Ferri, Clodoveo. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - STAMPA. - 14:(2012), pp. 97-104. [10.1007/s11912-012-0217-0]